Evolution of Novel Biopolymers

Lead Research Organisation: MRC Laboratory of Molecular Biology

Abstract

Every organism’s blueprint is stored as genetic information encoded in DNA. Before a cell can divide, its genetic information needs to be copied and duplicated. This process is carried out by sophisticated enzymes called polymerases. The astonishing ability of polymerases to both “read” and “write” genetic information is vital to all life on earth and central to modern biology and medicine enabling genome sequencing and the polymerase chain reaction. Our work is aimed at the engineering of novel polymerases capable of activity in unfavourable conditions, and utilising unnatural building blocks. Such "designer" polymerases will be key enabling technologies for the generation of next-generation nucleic acid drugs, sensors and nanomaterials.

Technical Summary

Synthetic biology seeks to probe biological form and function by construction (i.e. resynthesis) rather than deconstruction (analysis). Synthesis thus complements reductionist and analytic studies of life, and allows novel approaches towards fundamental biological questions.

We have been exploiting the synthesis paradigm to explore the chemical etiology of the genetic apparatus shared by all life on earth. Specifically, we ask why information storage and propagation in biological systems is based on just two types of nucleic acids, DNA and RNA. Is the chemistry of life’s genetic system based on chance or necessity? Does it reflect a "frozen accident", imposed at the origin of life, or are DNA and RNA functionally superior to simple alternatives.

We have developed advanced generation selection and screening strategies that have enabled the discovery of efficient polymerases and reverse transcriptases for the enzymatic synthesis, replication and evolution of synthetic genetic polymers (xeno-nucleic acids, XNAs) enabling the de novo selection of specific ligands (XNA aptamers) and catalysts (XNAzymes) based on these entirely synthetic backbones. Thus, key hallmarks of living systems, including heredity and evolution are not limited to DNA and RNA but can be implemented in synthetic genetic polymers and are likely to be emergent properties of any polymer capable of information storage.

The further exploration of the informational, structural and catalytic potential of synthetic genetic polymers, should advance our understanding of the parameters of chemical information encoding, and will provide a source of novel ligands, catalysts and nanostructures with tailor-made chemistries for applications in biotechnology and medicine.

We have also leveraged our selection technologies to make progress in the engineering and evolution of RNA polymerase ribozymes towards a general polymerase and self-replication capacity We have discovered RNA polymerase ribozymes (RPRs) that are capable of the templated synthesis (i.e. transcription) of another simple ribozyme or RNA oligomers exceeding their own size, a key milestone on the road to self-replication. Finally, we have discovered RPRs that utilize trinucleotide triphosphates (triplets) as substrates and show an unprecedented ability to copy structured RNAs including parts of the RPR itself thereby resolving a fundamental incongruity of RNA-catalysed RNA replication.

Publications

10 25 50
 
Description Royal Society Policy seminar on "Synthetic Biology"
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
 
Description Royal Society of Chemistry Replicating and Learning from Nature Exploration Workshop
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
 
Description 14-ERASynBio INTENSIFYBBSRC
Amount £287,638 (GBP)
Funding ID BB/M005623/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 07/2014 
End 07/2017
 
Description Artificial genetic systems with stereocontrolled sugar-phosphate backbone: towards advanced therapy and synthetic biology
Amount € 590,980 (EUR)
Organisation Research Foundation - Flanders (FWO) 
Sector Charity/Non Profit
Country Belgium
Start 04/2021 
End 04/2024
 
Description Blue Skies AZ/LMB BSF2-03
Amount £200,000 (GBP)
Funding ID BSF2-03 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start  
 
Description Blue Skies AZ/LMB BSF40
Amount £230,000 (GBP)
Funding ID BSF40 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 09/2021 
End 10/2023
 
Description Carlsberg Foundation
Amount £50,000 (GBP)
Organisation Carlsberg Foundation 
Sector Charity/Non Profit
Country Denmark
Start 09/2018 
End 09/2019
 
Description Carlsberg Foundation Internationalisation Fellowship (Kristofferson
Amount 425,000 kr. (DKK)
Funding ID CF19-0019 
Organisation Carlsberg Foundation 
Sector Charity/Non Profit
Country Denmark
Start 09/2019 
End 09/2020
 
Description DFG Fellowship (Baar)
Amount £48,000 (GBP)
Organisation German Research Foundation 
Sector Charity/Non Profit
Country Germany
Start 01/2007 
End 12/2008
 
Description DFG, Fellowship
Amount £37,805 (GBP)
Organisation German Research Foundation 
Sector Charity/Non Profit
Country Germany
Start 11/2004 
End 01/2006
 
Description EC - Marie Curie Fellowship (Gallego) DNA-origami frame platform for co-evolution ligand selection
Amount € 212,934 (EUR)
Funding ID H2020-MSCA-IF-2018-845303 
Organisation Marie Sklodowska-Curie Actions 
Sector Charity/Non Profit
Country Global
Start 03/2019 
End 03/2021
 
Description EMBO Advanced Fellowship - Furst
Amount € 120,000 (EUR)
Funding ID ALTF 648-2020 
Organisation European Molecular Biology Organisation 
Sector Charity/Non Profit
Country Germany
Start 04/2021 
End 04/2023
 
Description ERASynBio2 - Orthogonal biosystems based on phosphonate XNAs
Amount £250,283 (GBP)
Funding ID UCL Ref 168510 BB/N01023X/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 03/2016 
End 04/2019
 
Description EuroSynBio - SYNAPTA
Amount £334,000 (GBP)
Funding ID BB/I004793/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 04/2010 
End 04/2013
 
Description FEBS Fellowship
Amount £78,000 (GBP)
Organisation Federation of European Biochemical Societies (FEBS) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2012 
End 06/2015
 
Description FP6 NEST Pathfinder
Amount £403,381 (GBP)
Organisation Sixth Framework Programme (FP6) 
Sector Public
Country European Union (EU)
Start 04/2006 
End 07/2009
 
Description HFSP Fellowship
Amount £93,780 (GBP)
Funding ID LT000045/2012 
Organisation Human Frontier Science Program (HFSP) 
Sector Charity/Non Profit
Country France
Start 01/2013 
End 12/2015
 
Description Herchel Smith Studentship Christopher Wan
Amount £180,000 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 09/2021
 
Description Junior Research Fellowship
Amount £55,000 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start 09/2011 
End 09/2014
 
Description Leverhulme Early Career Fellowship - K Gerecht
Amount £100,000 (GBP)
Organisation The Leverhulme Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2021 
End 10/2023
 
Description MRC/AZ - CasEvo: directed evolution of CRISPR Cas function for advanced gene editing
Amount £110,000 (GBP)
Funding ID BSF43 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 01/2022 
End 01/2024
 
Description MRC/AZ CRISPR-X: Leveraging XNA technology for advanced genome editing
Amount £316,423 (GBP)
Funding ID BSF35 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 04/2019 
End 04/2022
 
Description MRC/AZ Deep screening: Leveraging NextGen sequencing technology for a quantum leap in ligand discovery
Amount £822,884 (GBP)
Funding ID BSF24 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 03/2017 
End 03/2023
 
Description MRC/AZ Explore XNA Aptamer technology for in vivo selection of targeting moieties and oligonucleotide delivery
Amount £215,642 (GBP)
Funding ID BSF01 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 05/2015 
End 06/2019
 
Description MRC/AZ In Cellulo target discovery using XNA technology
Amount £405,948 (GBP)
Funding ID BSF11 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 01/2016 
End 01/2020
 
Description MRCT DGF Project Grant
Amount £110,000 (GBP)
Funding ID A853-0137 
Organisation MRC-Technology 
Sector Private
Country United Kingdom
Start 08/2011 
End 09/2014
 
Description NSERC Canada fellowship
Amount £40,000 (GBP)
Organisation Natural Sciences and Engineering Research Council of Canada (NSERC) 
Sector Public
Country Canada
Start 09/2007 
End 12/2008
 
Description Simons Collaboration on the Origins of Life Postdoctoral Fellowship
Amount $243,000 (USD)
Funding ID 293387 
Organisation Simons Foundation 
Sector Charity/Non Profit
Country United States
Start 11/2013 
End 10/2016
 
Description US Gates - Duffy
Amount £44,700 (GBP)
Organisation University of Cambridge 
Department Gates Cambridge Trust
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2019
 
Description VolkswagenStiftung
Amount € 396,000 (EUR)
Organisation Volkswagen Foundation 
Sector Charity/Non Profit
Country Germany
Start  
 
Description Wellcome Trust Internship
Amount £1,360 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2006 
End 08/2006
 
Title CSR 
Description polymerases with expanded substrate spectrum 
Type Of Material Technology assay or reagent 
Year Produced 2008 
Provided To Others? Yes  
Impact licensing deals with New England Biolabs, Human Genetic Signatures 
 
Title CST 
Description novel polymerases capable of utilizing entirely unnatural orthogonal substrates 
Type Of Material Technology assay or reagent 
Year Produced 2010 
Provided To Others? Yes  
Impact improved tools for e.g. generation of nucleic acid therapeutics 
 
Description CryoEM imaging of XNA nanotechnology objects 
Organisation Medical Research Council (MRC)
Department MRC Laboratory of Molecular Biology (LMB)
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact first structures of XNA nano-object
 
Description CyDNA in super-resolution microscopy 
Organisation University of Edinburgh
Department School of Chemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact publication: 22861666 (August, 2012) Reversible Fluorescence Photoswitching in DNA.
 
Description DNA/XNA origami nanopores 
Organisation University of Cambridge
Department Department of Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Deep Screening 
Organisation ETH Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Hydrophobic base analogues 
Organisation Stanford University
Department Department of Chemistry
Country United States 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description In vivo target discovery 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description LNA and UNA triphosphates as polymerase substrates 
Organisation University of Southern Denmark
Country Denmark 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Mutant Polymerases 
Organisation Agilent Technologies
Country United States 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation Exiqon
Country Denmark 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation Helicos Biosciences
Country United States 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation Life Technologies
Department Applied Biosystems
Country United States 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation Life Technologies
Department Invitrogen
Country United Kingdom 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation New England Biolabs
Country United States 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Mutant Polymerases 
Organisation Solexa
Country United States 
Sector Private 
PI Contribution generation of novel polymerases with potential biotechnological impact
Collaborator Contribution non-exclusive license for both polymerases and CSR selection technology potential for collaboration
Impact generation of licensing revenue for MRC
 
Description Oligonucleotide arrays 
Organisation Agilent Technologies
Country United States 
Sector Private 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Phage Display 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution consulting for GSK/ Domantis dispute with AbLynx
Collaborator Contribution GSK/ Domantis dispute with AbLynx
Impact contribution to settlement
Start Year 2008
 
Description Polymerase Evolution 
Organisation Domantis Ltd
Country United Kingdom 
Sector Private 
PI Contribution development of novel directed evolution methodologies for proteins and in particular polymerases
Collaborator Contribution Collaboration agreement with Domantis funded 2 postdoctoral scientists in my group
Impact funding of postdoctoral researchers, cost of patent prosecution, consumables; Collaboration agreement with Domantis funded 2 postdoctoral scientists in my group
 
Description Polymerases for Bisulfite Sequencing 
Organisation Human Genetic Signatures
Country Australia 
Sector Private 
PI Contribution evaluation agreement
Collaborator Contribution evaluation agreement
Impact evaluation agreement
Start Year 2008
 
Description SHAPE mapping of XNAs and RNAs 
Organisation University of Notre Dame
Department Department of Chemistry and Biochemistry
Country United States 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact publication: 25470036 (February, 2015) Catalysts from synthetic genetic polymers.
 
Description Structural studies of XNA polymerases. 
Organisation University of Konstanz
Department Department of Chemistry
Country Germany 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact 23940661 (, 2013) Structures of an apo and a binary complex of an evolved archeal B family DN...
 
Description TNA triphosphates as polymerase substrates. 
Organisation Arizona State University
Department School of Molecular Sciences
Country United States 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Translesion synthesis of XNA polymerases 
Organisation National Institutes of Health (NIH)
Department Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Country United States 
Sector Public 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description Unnatural base-pair replication in RNA. 
Organisation RIKEN
Department RIKEN centre for life science technologies
Country Japan 
Sector Public 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description X-ray crystallography of mutant DNA polymerases. 
Organisation Medical Research Council (MRC)
Department MRC Laboratory of Molecular Biology (LMB)
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description XNA nucleotide and solid-phase synthesis. 
Organisation University of Leuven
Department Rega Institute for Medical Research
Country Belgium 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Description XNA side-chain modification chemistry 
Organisation University of Bonn
Country Germany 
Sector Academic/University 
PI Contribution Scientific
Collaborator Contribution Scientific
Impact N/A
 
Title CST (COMPARTMENTALISED SELF TAGGING) 
Description The present invention relates to the development of a novel method for the selection of nucleic acid processing and other enzymes. In particular the invention relates to, a method for the selection of nucleic acid polymerases and other enzymes with desired properties based on the method of compartmentalized self-tagging. 
IP Reference WO2005045072 
Protection Patent granted
Year Protection Granted 2005
Licensed Yes
Impact A novel method for the selection of nucleic acid processing and other enzymes based on the compartmentalized self-tagging technique
 
Title CST2.0 
Description improved methodology for CST emulsions, filed as a continuation in part 
IP Reference US20100184071 
Protection Patent granted
Year Protection Granted 2010
Licensed No
Impact Significant improvement on CST (compartmentalised self tagging) method which is already patented and relates to screening of polymerases with specific properties. The method allows for selection of only true positives which was frequently not the case with the original CST.
 
Title DIRECTED EVOLUTION METHOD 
Description We describe a method of selecting an enzyme having replicase activity, the method comprising the steps of: (a) providing a pool of nucleic acids comprising members each encoding a replicase or a variant of the replicase; (b) subdividing the pool of nucleic acids into compartments, such that each compartment comprises a nucleic acid member of the pool together with the replicase or variant encoded by the nucleic acid member; (c) allowing nucleic acid replication to occur; and (d) detecting amplification of the nucleic acid member by the replicase. Methods for selecting agents capable of modulating replicase activity, and for selecting interacting polypeptides are also disclosed. 
IP Reference WO0222869 
Protection Patent granted
Year Protection Granted 2002
Licensed Yes
Impact Method to select for proteins with altered characteristics. The protein of interest is randomly mutated and variants of it undergo selection based on presence or absence of nucleic acid polymerase activity.
 
Title ENZYMES 
Description The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide polymer template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO: 12. The invention also relates to A nucleic acid polymerase capable of reverse transcribing a HNA nucleotide polymer into a DNA nucleotide polymer, said polymerase comprising amino acid sequence having at least 36 % identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue 1521. 
IP Reference WO2011135280 
Protection Patent application published
Year Protection Granted 2011
Licensed No
Impact NA
 
Title Emulsion compositions 
Description An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system. 
IP Reference US2008187968 
Protection Patent granted
Year Protection Granted 2008
Licensed Yes
Impact Invention describes improved chemical composition of two phase emulsions. Such emulsions are of use for large scale screening
 
Title POLYMERASE 
Description The present invention relates to an engineered polymerase characterized in that the polymerase exhibits an enhanced ability to process nucleic acid in the presence of environmental and biological inhibitors compared to wild type DNA polymerase. 
IP Reference US2009305345 
Protection Patent granted
Year Protection Granted 2009
Licensed Yes
Impact improved diagnostic & forensic PCR assays, ancient DNA research
 
Title POLYMERASE 
Description The present invention relates to an engineered polymerase with an expanded substrate range characterized in that the polymerase is capable of incorporating an enhanced occurrence of detection agent-labeled nucleotide analogue into nucleic acid synthesized by that engineered polymerase as compared with the wild type polymerase from which it is derived. 
IP Reference US2010035767 
Protection Patent granted
Year Protection Granted 2010
Licensed Yes
Impact improved microarray protocols, novel diagnostics
 
Title POLYMERASE CAPABLE OF PRODUCING NON-DNA NUCLEOTIDE POLYMERS. 
Description The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide polymer template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO: 1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO: 1, wherein said amino acid sequence comprises the mutations P657T, E658Q, K659H, Y663H, D669Alpha, K671N, and T676I; wherein said amino acid sequence is further mutated relative to the amino acid sequence of SEQ ID NO: 1 at residue: E664 and wherein said amino acid sequence comprises the mutation E664K. The invention also relates to methods of making nucleotide polymers comprising use of this polymerase. Suitably the nucleotides are arabino nucleotides such as ARA: or FANA nucleotides. 
IP Reference WO2013156786 
Protection Patent application published
Year Protection Granted 2013
Licensed No
Impact none
 
Title Polymerase 
Description polymerases with increased ability for mismatch extension, enhanced processivity and expanded substrate spectrum 
IP Reference AU2010200031 
Protection Patent granted
Year Protection Granted 2010
Licensed Yes
Impact Method for the generation of DNA polymerases which exhibit relaxed substrate specificity
 
Description BBC Discovery program, World service 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Radio interview

NA
Year(s) Of Engagement Activity 2010
 
Description BBC4 radio program 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Radio science program

NA
Year(s) Of Engagement Activity 2010
 
Description Cambridge Science Society talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Gave talk at Cambridge Scientific Society with more than 1000 permanent members (and a much larger email database). The Society is a prestigious platform for the first public exposure of new research and findings. Past speakers include Nobel Laureates James Watson, Sir Tim Hunt and Sir John Walker, eminent scientists Sir Roger Penrose, Sir Richard Friend, Sir John Beddington and Peter Atkins, popular author Matt Ridley, and former Universities and Sciences minister David Willetts among many others.

Tlk was well received by ca. 100 attendees and prompted many discussions and online Tweets.
Year(s) Of Engagement Activity 2016
URL http://www.scisoc.com/talks/
 
Description New Scientist Instant Expert Lecture series: Origins of life 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Lecture as part of New Scientist Instant Expert Lecture series: Origins of life
Year(s) Of Engagement Activity 2017
 
Description New polymerases for old DNA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact talk on "Second Nature", Nature publishings virtual web conference site in Second Life

follow up questions from public by e-mail
Year(s) Of Engagement Activity 2008
 
Description Online blog Nature Chemistry Community 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Online blog Nature Chemistry Community: Holliger P (2019) Genetic function without charge. Nature Research Chemistry Community.
Year(s) Of Engagement Activity 2019
URL https://chemistrycommunity.nature.com/posts/48237-genetic-function-without-charge
 
Description Online blog Nature Chemistry Community 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Online blog Nature Chemistry Community: Houlihan G & Holliger P (2020) A new route to reverse transcriptases. Nature Research Chemistry Community
Year(s) Of Engagement Activity 2020
URL https://chemistrycommunity.nature.com/posts/a-new-route-to-reverse-transcriptases
 
Description Orthosome 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact describe FP6 funded project : orthosome on website

feedback on project, attract students
Year(s) Of Engagement Activity 2007
 
Description Press article 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact phone interview for Guardian article "Biologists join the race to create synthetic life"

article
Year(s) Of Engagement Activity 2008
 
Description Public lecture 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact New Scientist Instant Expert: Origins and Evolution of Life event at The Royal College of General Practitioners
Year(s) Of Engagement Activity 2017
URL https://www.nature.com/natureevents/science/events/58969-New_Scientist_Instant_Expert_The_Origins_of...
 
Description RSC Policy seminar 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact seminar to public / policymakers about impact and future of synthetic biology

interviews with journalists e.g. Today program, Guardian science podcast etc.
Year(s) Of Engagement Activity 2008
 
Description RSC discussion meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact RSC 2 day discussion meeting for ca. 120 leading academics, policymakers and other stakeholders

RSC published summary booklet
Year(s) Of Engagement Activity 2008
 
Description Radio interview (Deutschlandfunk 2013) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact radio interview
Year(s) Of Engagement Activity 2013
URL http://www.dradio.de/dlf/sendungen/forschak/2171572/
 
Description Royal Society Summer Science Exhibition 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Members of my lab were involved in presenting a stand at the Royal Society Summer Science Exhibition
Year(s) Of Engagement Activity 2019
 
Description Talk , LMB Alumni symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact talk sparked question and discussions afterwards

increased interest in my research
Year(s) Of Engagement Activity 2014
URL http://www2.mrc-lmb.cam.ac.uk/alumnisymposium/programme.php
 
Description Talk at Cambridge Synthetic Biology Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Talk at Cambridge Synthetic Biology Society attended by ca. 50-100 students at Pfizer Lecture Theatre at Cambridge University, which sparked questions and discussion afterwards, and an interest in students wishing to join my lab or learn more about our research.
Year(s) Of Engagement Activity 2020
 
Description Talk for non-scientific staff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact talk sparked questions and discussion afterwards

better understanding of my research by support staff
Year(s) Of Engagement Activity 2014
 
Description eLife Biochemistry and chemical biology webinar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact eLife Biochemistry and chemical biology webinar series (with Phil Cole (Harvard, eLife senior editor), Emily Balskus (Harvard), James A. Wells (UCSF), Yamuna Krishnan (U. of Chicago)): Small molecules, big molecules, and beyond
Year(s) Of Engagement Activity 2018
URL https://elifesciences.org/inside-elife/70884b36/webinar-report-small-molecules-big-molecules-and-bey...
 
Description eLife Podcast 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact eLife Podcast on our work on Triplet-based RNA replication
Year(s) Of Engagement Activity 2018
URL https://prod--journal.elifesciences.org/podcast/episode49#36